Okada N, Kaneda Y, Miyamoto H, Yamamoto Y, Mizuguchi H, Tsutsumi Y, Nakagawa S, Mayumi T
Faculty and Graduate School of Pharmaceutical Sciences, Osaka University.
Jpn J Cancer Res. 1996 Aug;87(8):831-6. doi: 10.1111/j.1349-7006.1996.tb02107.x.
We have previously developed a simple and quantitative method for assessment of in vivo tumor cell-induced angiogenesis by means of microencapsulation of tumor cells in agarose hydrogel and mouse hemoglobin ELISA (mHb-ELISA). In this article, we report that the new blood vessels induced with agarose-encapsulated tumor cells have the same sensitivity to tumor necrosis factor-alpha (TNF-alpha) as the original solid-tumor vessels. Agarose beads (average diameter = 200 microns), in which Meth-A fibrosarcoma cells were microencapsulated, were subcutaneously implanted in non-syngeneic ddY mice. Ten days later, extensive angiogenesis was observed on the implanted sites of Meth-A agarose heads, whereas no new blood vessels were induced with cell-free agarose heads. The vascular permeability of the new blood vessels induced with agarose-microencapsulated Meth-A cells was selectively and significantly enhanced by the i.v. injection of TNF-alpha, and it reached the maximum level at 2 h after the injection of TNF-alpha. At 4 h after the injection of TNF-alpha, the vascular permeability was reduced to the basal level. This permeability profile in Meth-A agarose beads in ddY mice is very similar to that in Meth-A solid tumor in syngeneic BALB/c mice. On the other hand, TNF-alpha-treatment did not affect the vascular permeability of other normal tissues or inflammatory tissue in ddY mice. These results strongly suggest that the new blood vessels induced with agarose-microencapsulated tumor cells have the specific characteristics of tumor vessels. Our in vivo angiogenesis assay system should be useful not only to screen anti-angiogenetic agents, but also to elucidate the mechanism of tumor angiogenesis.
我们之前开发了一种简单且定量的方法,通过将肿瘤细胞微囊化于琼脂糖水凝胶中,并采用小鼠血红蛋白酶联免疫吸附测定法(mHb - ELISA)来评估体内肿瘤细胞诱导的血管生成。在本文中,我们报告称,由琼脂糖包封的肿瘤细胞诱导生成的新血管对肿瘤坏死因子 - α(TNF - α)的敏感性与原始实体瘤血管相同。将微囊化有Meth - A纤维肉瘤细胞的琼脂糖珠(平均直径 = 200微米)皮下植入非同源的ddY小鼠体内。十天后,在植入Meth - A琼脂糖珠的部位观察到广泛的血管生成,而无细胞的琼脂糖珠未诱导出新血管。静脉注射TNF - α可选择性且显著增强由琼脂糖微囊化的Meth - A细胞诱导生成的新血管的血管通透性,且在注射TNF - α后2小时达到最高水平。在注射TNF - α后4小时,血管通透性降至基础水平。ddY小鼠体内Meth - A琼脂糖珠中的这种通透性特征与同源BALB / c小鼠体内Meth - A实体瘤中的非常相似。另一方面,TNF - α处理对ddY小鼠的其他正常组织或炎症组织的血管通透性没有影响。这些结果有力地表明,由琼脂糖微囊化肿瘤细胞诱导生成的新血管具有肿瘤血管的特定特征。我们的体内血管生成检测系统不仅应有助于筛选抗血管生成剂,还应有助于阐明肿瘤血管生成的机制。